111 related articles for article (PubMed ID: 29038654)
1. CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells.
Riehn M; Cebula M; Hauser H; Wirth D
Front Immunol; 2017; 8():1201. PubMed ID: 29038654
[TBL] [Abstract][Full Text] [Related]
2. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
5. CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes.
Sacher T; Knolle P; Nichterlein T; Arnold B; Hämmerling GJ; Limmer A
Eur J Immunol; 2002 Dec; 32(12):3628-37. PubMed ID: 12516551
[TBL] [Abstract][Full Text] [Related]
6. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
Rattanakiat S; Nishikawa M; Takakura Y
Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
[TBL] [Abstract][Full Text] [Related]
7. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
[TBL] [Abstract][Full Text] [Related]
8. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
[TBL] [Abstract][Full Text] [Related]
9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine-phosphate-guanosine-oligodeoxynucleotides and model tumor antigen.
Inoue J; Aramaki Y
J Invest Dermatol; 2007 Mar; 127(3):614-21. PubMed ID: 17159912
[TBL] [Abstract][Full Text] [Related]
12. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
15. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides.
Wang Y; Krieg AM
Vaccine; 2004 Jun; 22(20):2641-50. PubMed ID: 15193390
[TBL] [Abstract][Full Text] [Related]
16. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
17. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
18. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA.
Suzuki K; Suda T; Naito T; Ide K; Chida K; Nakamura H
Am J Respir Crit Care Med; 2005 Apr; 171(7):707-13. PubMed ID: 15640365
[TBL] [Abstract][Full Text] [Related]
19. [The synergistic effects of lipopolysaccharide, bacterial lipoprotein and bacterial DNA on mouse alveolar macrophage activation].
Huang H; Jiang JX; Zhu PF; Wang ZG; Zhang DJ; Yang C
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1468-72. PubMed ID: 16061024
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
